Your browser is no longer supported. Please, upgrade your browser.
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.91 Insider Own0.40% Shs Outstand60.30M Perf Week-1.15%
Market Cap8.17B Forward P/E- EPS next Y-1.21 Insider Trans-35.76% Shs Float52.57M Perf Month17.59%
Income-166.00M PEG- EPS next Q-0.66 Inst Own89.90% Short Float4.20% Perf Quarter15.37%
Sales92.50M P/S88.30 EPS this Y-22.80% Inst Trans-0.15% Short Ratio6.57 Perf Half Y41.95%
Book/sh14.18 P/B9.58 EPS next Y21.30% ROA-23.50% Target Price141.08 Perf Year50.36%
Cash/sh14.14 P/C9.61 EPS next 5Y- ROE-25.70% 52W Range66.44 - 144.26 Perf YTD6.18%
Dividend- P/FCF- EPS past 5Y-8.80% ROI-19.60% 52W High-5.83% Beta0.42
Dividend %- Quick Ratio14.80 Sales past 5Y38.60% Gross Margin- 52W Low104.47% ATR6.67
Employees312 Current Ratio14.80 Sales Q/Q-34.10% Oper. Margin- RSI (14)57.17 Volatility5.74% 4.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-114.40% Profit Margin- Rel Volume1.25 Prev Close135.85
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume335.94K Price135.85
Recom1.90 SMA203.24% SMA506.59% SMA20023.02% Volume0 Change0.00%
Nov-06-20Reiterated H.C. Wainwright Buy $137 → $148
Aug-25-20Initiated Raymond James Strong Buy $155
Apr-06-20Downgrade Goldman Neutral → Sell $73
Feb-27-20Initiated Barclays Overweight $107
Feb-03-20Upgrade Morgan Stanley Equal-Weight → Overweight $122
May-29-19Resumed Goldman Neutral
May-24-19Resumed Citigroup Buy $66
May-03-19Downgrade Barclays Overweight → Equal Weight $54 → $45
Apr-22-19Resumed Oppenheimer Outperform
Feb-28-19Reiterated H.C. Wainwright Buy $72 → $67
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Mar-01-21 04:33PM  
Feb-27-21 09:23AM  
Feb-26-21 12:31PM  
Feb-25-21 05:00PM  
Feb-23-21 07:00AM  
Feb-17-21 07:00AM  
Feb-16-21 12:13PM  
Feb-04-21 07:10AM  
Jan-19-21 01:29PM  
Jan-04-21 07:00AM  
Dec-30-20 08:17AM  
Dec-22-20 04:30PM  
Dec-21-20 10:01AM  
Dec-18-20 10:07AM  
Dec-15-20 09:22AM  
Dec-14-20 07:00AM  
Dec-11-20 09:03AM  
Dec-05-20 11:32AM  
Dec-02-20 06:03PM  
Dec-01-20 07:00AM  
Nov-16-20 11:41PM  
Nov-13-20 10:01AM  
Nov-09-20 07:00AM  
Nov-06-20 11:05AM  
Nov-05-20 06:15PM  
Nov-04-20 04:01PM  
Oct-29-20 12:34PM  
Oct-28-20 02:46PM  
Oct-26-20 04:02PM  
Sep-30-20 07:45AM  
Sep-29-20 06:59AM  
Sep-17-20 04:01PM  
Sep-16-20 07:00AM  
Sep-13-20 10:55AM  
Sep-05-20 11:31AM  
Aug-31-20 10:35PM  
Aug-26-20 10:44PM  
Aug-07-20 10:36AM  
Aug-06-20 06:15PM  
Aug-03-20 10:14AM  
Jul-30-20 12:33PM  
Jul-27-20 12:31PM  
Jul-23-20 05:12PM  
Jul-13-20 07:16PM  
Jul-11-20 05:42PM  
Jul-07-20 04:04PM  
Jul-06-20 05:01PM  
Jul-02-20 09:03AM  
Jun-30-20 06:48PM  
Jun-29-20 04:01PM  
Jun-26-20 09:05AM  
Jun-24-20 04:29PM  
Jun-22-20 07:00AM  
Jun-11-20 07:30AM  
Jun-10-20 11:30AM  
Jun-04-20 04:05PM  
Jun-01-20 02:58PM  
May-20-20 07:00AM  
May-19-20 07:00AM  
May-13-20 04:01PM  
May-12-20 04:31PM  
May-11-20 05:45PM  
May-05-20 07:00AM  
May-04-20 07:00AM  
May-02-20 04:32PM  
Apr-30-20 04:16PM  
Apr-24-20 11:41AM  
Apr-21-20 05:31PM  
Apr-09-20 02:24PM  
Apr-08-20 02:38PM  
Apr-07-20 04:05PM  
Apr-06-20 10:03PM  
Apr-03-20 05:08PM  
Mar-29-20 07:38PM  
Mar-26-20 06:59AM  
Mar-09-20 04:05PM  
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Veness Adam MSVP, General Counsel and Sec.Jan 05Sale122.562,056251,98816,163Jan 06 07:12 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 05Sale121.401,499181,9825,813Jan 06 07:03 PM
Dable Habib JCEO and PresidentJan 05Sale121.134,258515,77481,788Jan 06 06:58 PM
KANGO SUJAYEVP, Chief Commercial OfficerJan 04Sale125.3810,0001,253,7593,987Jan 06 07:09 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 04Sale124.083,280406,9927,312Jan 06 07:03 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 14Option Exercise32.2942,5281,373,15953,744Dec 15 06:24 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 14Sale130.1442,5285,534,59411,216Dec 15 06:24 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 11Option Exercise41.203,100127,72014,316Dec 11 06:08 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 11Sale125.003,100387,50011,216Dec 11 06:08 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 10Option Exercise33.5850016,79211,716Dec 11 06:08 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 10Sale125.1250062,56011,216Dec 11 06:08 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 09Option Exercise36.553,872141,53715,088Dec 11 06:08 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 09Sale125.033,872484,11611,216Dec 11 06:08 PM
Kearney Terrence CDirectorOct 12Option Exercise28.6237,5001,073,37542,627Oct 13 07:14 PM
Kearney Terrence CDirectorOct 12Sale119.3637,5004,475,9815,127Oct 13 07:14 PM
MCCOURT Thomas ADirectorSep 11Option Exercise32.5823,272758,31627,694Sep 15 04:51 PM
MCCOURT Thomas ADirectorSep 11Sale90.3923,2722,103,4664,422Sep 15 04:51 PM
Veness Adam MSVP, General Counsel and Sec.Sep 08Sale89.502,000179,00419,161Sep 09 05:49 PM
CELGENE CORP /DE/10% OwnerJul 09Sale102.282,241229,2097,008,510Jul 13 06:27 PM
Dable Habib JCEO and PresidentJul 01Option Exercise35.0450,0001,752,000139,324Jul 06 06:57 PM
CELGENE CORP /DE/10% OwnerJul 01Buy92.50108,1089,999,9906,971,772Jul 06 05:24 PM
Dable Habib JCEO and PresidentJul 01Sale96.4150,0004,820,44589,324Jul 06 06:57 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Option Exercise41.2017,226709,71128,442Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Sale88.1917,2261,519,16111,216Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Option Exercise32.7436,7741,204,12947,990Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Option Exercise27.976,000167,82027,161Apr 10 05:30 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Sale85.586,000513,50921,161Apr 10 05:30 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Sale85.5136,7743,144,61411,216Apr 10 05:29 PM